Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.

CONTEXT The percentage of free prostate-specific antigen (PSA) in serum has been shown to enhance the specificity of PSA testing for prostate cancer detection, but earlier studies provided only preliminary cutoffs for clinical use. OBJECTIVE To develop risk assessment guidelines and a cutoff value for defining abnormal percentage of free PSA in a population of men to whom the test would be applied. DESIGN Prospective blinded study using the Tandem PSA and free PSA assays (Hybritech Inc, San Diego, Calif). SETTING Seven nationwide university medical centers. PARTICIPANTS A total of 773 men (379 with prostate cancer, 394 with benign prostatic disease) 50 to 75 years of age with a palpably benign prostate gland, PSA level of 4.0 to 10.0 ng/mL, and histologically confirmed diagnosis. MAIN OUTCOME MEASURES A percentage of free PSA cutoff that maintained 95% sensitivity for prostate cancer detection, and probability of cancer for individual patients. RESULTS The percentage of free PSA may be used in 2 ways: as a single cut-off (ie, perform a biopsy for all patients at or below a cutoff of 25% free PSA) or as an individual patient risk assessment (ie, base biopsy decisions on each patient's risk of cancer). The 25% free PSA cutoff detected 95% of cancers while avoiding 20% of unnecessary biopsies. The cancers associated with greater than 25% free PSA were more prevalent in older patients, and generally were less threatening in terms of tumor grade and volume. For individual patients, a lower percentage of free PSA was associated with a higher risk of cancer (range, 8%-56%). In the multivariate model used, the percentage of free PSA was an independent predictor of prostate cancer (odds ratio [OR], 3.2; 95% confidence interval [CI], 2.5-4.1; P < .001) and contributed significantly more than age (OR, 1.2; 95% CI, 0.92-1.55) or total PSA level (OR, 1.0; 95% CI, 0.92-1.11) in this cohort of subjects with total PSA values between 4.0 and 10.0 ng/mL. CONCLUSIONS Use of the percentage of free PSA can reduce unnecessary biopsies in patients undergoing evaluation for prostate cancer, with a minimal loss in sensitivity in detecting cancer. A cutoff of 25% or less free PSA is recommended for patients with PSA values between 4.0 and 10.0 ng/mL and a palpably benign gland, regardless of patient age or prostate size. To our knowledge, this study is the largest series to date evaluating the percentage of free PSA in a population representative of patients in whom the test would be used in clinical practice.

[1]  B. Tombal,et al.  Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSA. , 1996, Urology.

[2]  C. Cuny,et al.  Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. , 1996, Urology.

[3]  M. J. Hoeksema,et al.  Cancer mortality rates fall: a turning point for the nation. , 1996, Journal of the National Cancer Institute.

[4]  B. Efron.  The jackknife, the bootstrap, and other resampling plans , 1987 .

[5]  D. Ornstein,et al.  Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. , 1997, JAMA.

[6]  J. Oesterling,et al.  Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate. , 1996, Urology.

[7]  J. Oesterling,et al.  Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. , 1995, The Journal of urology.

[8]  E. Metter,et al.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. , 1992, JAMA.

[9]  S. Loening,et al.  Analytical performance and clinical validity of two free prostate-specific antigen assays compared. , 1996, Clinical chemistry.

[10]  L. Baert,et al.  Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer. , 1996, The Journal of urology.

[11]  B. Tombal,et al.  Free to total prostate‐specific antigen (PSA) ratio is superior to total‐PSA in differentiating benign prostate hypertrophy from prostate cancer , 1996, The Prostate. Supplement.

[12]  P. Schellhammer,et al.  Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. , 1997, Urology.

[13]  W. Catalona,et al.  Longitudinal screening for prostate cancer with prostate-specific antigen. , 1996, JAMA.

[14]  W. Catalona,et al.  Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. , 1995, JAMA.

[15]  W. Catalona,et al.  Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. , 1998, The Journal of urology.

[16]  David W. Hosmer,et al.  Applied Logistic Regression , 1991 .

[17]  O. Nilsson,et al.  Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. , 1993, The Journal of urology.

[18]  B. Efron.  Better Bootstrap Confidence Intervals , 1987 .

[19]  B. G. Blijenberg,et al.  The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma. , 1997, The Journal of urology.

[20]  U. Stenman,et al.  A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. , 1991, Cancer research.

[21]  M. Brawer,et al.  Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. , 1995, Urology.

[22]  E. Metter,et al.  Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. , 1997, Urology.

[23]  Allen C. Goodman,et al.  Economic considerations of prostate cancer. The role of detection specificity and biopsy reduction , 1995 .

[24]  A W Partin,et al.  Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. , 1996, Urology.

[25]  J. Shaffer,et al.  Analytical performance of the Tandem-R free PSA immunoassay measuring free prostate-specific antigen. , 1997, Clinical chemistry.

[26]  W. Catalona,et al.  Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. , 1994, The Journal of urology.

[27]  H. Lilja,et al.  Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. , 1990, European journal of biochemistry.

[28]  M. Stampfer,et al.  A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. , 1995, JAMA.